Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EB 002 - Enveric Biosciences

X
Drug Profile

EB 002 - Enveric Biosciences

Alternative Names: EB-002 - Enveric Biosciences; EB-373; psilocin prodrug - Enveric Biosciences

Latest Information Update: 15 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Enveric Biosciences
  • Class Anxiolytics; Behavioural disorder therapies; Indole alkaloids; Mood stabilisers; Small molecules; Tryptamines
  • Mechanism of Action Serotonin 5-HT2A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Anxiety disorders

Most Recent Events

  • 10 Jul 2024 Enveric Biosciences has patent protection for methods of treating a broad range of neurological disorders using EB 002 in USA
  • 26 Mar 2024 Enveric Biosciences plans a first-in-human phase I trial for Anxiety disorders in Australia (PO), in 2024
  • 27 Dec 2023 Pharmacokinetics and adverse event data from a preclinical trial in Anxiety disorder released by Enveric Biosciences
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top